← All candidates
112 insider filings on record.
Gilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 20 Aug · filed 10 Sep · selfBuy$1K–$15Kself20 Aug27d ago10 Sep6d agoGilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 3 Mar · filed 7 Apr · selfBuy$1K–$15Kself3 Mar197d ago7 Apr162d ago112 filings on record.
AGIOAGIOS PHARMACEUTICALS, INC.
NasdaqGS · Healthcare · $1.98B
$34.63
+3.22% · Sep 9
112 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 34 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.98B
Float
50.0M
84% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
20.1
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
Congress
▸ Disclosures lag trades by 30–45 days.
3 disclosures12 mo
MemberTypeAmountOwnerTradedFiled
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
107 more transactions on Pro →Context
Wall St
$40.75 avg target
+17.7% vs today · 8 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$1.69 act+$0.10
Q4 '25−$1.85 act+$0.09
Q3 '25−$1.78 act+$0.12
Q2 '25−$1.93 act−$0.18
Coverage
AGIO Stock Surges 35% in Six Months: What's Driving It?Zacks · 06-18Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain MissMarketBeat · 06-13How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO)Simply Wall St. · 06-03AGIO Secures Global Rights to Late-Stage Rare Blood Disorder CandidateZacks · 06-02
The file stays open
112 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice